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1. Introduction 
Because gliomas are not curable surgically, development of effective adjuvant therapies is 
warranted. A chemotherapeutic agent temozolimide (TMZ) has been widely used not only 
because it is well tolerated and easily administrated orally but because various clinical trials 
had revealed that high grade gliomas could show objective response or stable disease to this 
compound (Stupp et al., 2005). The action of TMZ had been extensively studied primarily in 
leukemia and lymphoma cells. TMZ spontaneously decomposes in aqueous solution to form 
the cytotoxic methylating agent, and the cytotoxicity of TMZ appears to be mediated mainly 
through adduction of a methyl group to O6 position of guanine (G) in genomic DNA. The 
methyl group can be removed from O6-methylguanine by O6-methylguanine-DNA 
methyltransferase (MGMT).  If MGMT is deficient in the cell, however, O6-methylguanine is 
not repaired, and incorporation of a thymine (T) rather than a cytosine opposite the O6-
methylguanine during the next cycle of DNA replication leads to the formation of GT 
mismatches in DNA. This triggers the DNA mismatch repair (MMR) system which removes 
the T, only to have the T reinserted during repair synthesis. Futile cycles of MMR triggered 
by GT mismatches can lead to a variety of outcomes in TMZ-treated cells (Figure 1). 
 
 
Fig. 1. Mechanism of temozolomide-induced DNA damage creation 
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Since MGMT has been considered as a key factor in the resistance of gliomas to TMZ, 
several clinical trials have been conducted. However, TMZ treatment in combination with 
MGMT-depleting compound did not show remarkable therapeutic affect for malignant 
gliomas, and recent clinical studies suggest that MGMT is just a prognostic marker for 
malignant gliomas treated with genotoxic agents including radiation and chemotherapy, 
and that MGMT is not the only factor that induces TMZ-resistance, and that further 
biological investigation on glioma cells is needed. In this chapter we review our studies on 
glioma biology in regard its cellular responses to DNA-damaging compounds, especially 
TMZ, which could provide a clue to develop safe and effective methods to potentiate anti-
tumor activity of the drug. 
2. Cell cycle arrest of glioma cells in response to temozolomide 
Most of DNA-damaging chemotherapeutic agents induce cell cycle arrest, and so does TMZ 
(Hirose et al., 2001a). When MGMT-negative and p53 wildtype U87MG human glioblastoma 
cells were treated with TMZ at the concentration based on the published data of the plasma 
concentration of the drug in patients involved in its clinical trials (100 microM for 3 hours), 
FACS analysis revealed no significant difference in the percentage of cells in each phase of 
the cell cycle between untreated U87MG cells and the cells harvested at 1 day after TMZ 
treatment. However, cells began to accumulate at the G2/M boundary (4n DNA content) 2 
days after TMZ treatment. This G2/M arrest (here defined as a greater percentage of cells in 
G2/M than G1) was sustained for at least 10 days after TMZ treatment, and was associated 
with the gradual appearance of hyperploid (>4n DNA content) cells and the gradual loss of 
cells with 2n DNA content (G1 cells). Although TMZ-treated cells underwent cell cycle 
arrest, the sub-G1 population, which represents apoptotic cells, was small and did not 
significantly increase throughout the 10 days following TMZ treatment. Consistent with the 
G2/M arrest data, p53 and p21Waf1/Cip1 levels were increased approximately 2-4 fold at 2 
days after TMZ treatment with the accumulation persisting at least 10 days after the 
treatment. On the other hand, genetically modified U87MG-E6 cells which have low levels 
of p53 because of transfection of human papilloma viral oncoprotein E6 mediating 
ubiquitination and destruction of p53 showed shorter G2/M after TMZ treatment. That is, 
the proportion of U87MG cells at G2/M began decreasing by 3 days after TMZ treatment 
and was considerably lessened by 10 days after treatment. The reduction in G2/M arrest in 
these cells was also associated with a gradual increase in cells with a sub-G1 (less than 2n).  
Because U87MG and U87MG-E6 cells share a common genetic background except for 
expression of E6, comparison of the responses of these cells provides more useful 
information than the comparison of responses of cells with completely different genetic 
backgrounds. These results support the idea that p53 (and p21Waf1/Cip1), while not important 
for initiation of TMZ-induced G2/M arrest, do play a role in sustaining the arrest (Figure 2). 
Colony formation efficiency assay revealed that U87MG cells showed a dose-dependent 
decrease in clonogenicity, and, on the other hand, U87MG-E6 cells formed far less colonies. 
As well as being associated with the duration of TMZ-induced arrest in glioma cells, the p53 
status of cells was also associated with the ultimate fate of the cells. p53-wildtype cells 
underwent a prolonged G2/M arrest which left the majority of cells viable yet non-
proliferative showing the features of ascent cells. In contrast, p53-deficient cells underwent a 
more transient arrest, and lost viability in a manner consistent with mitotic catastrophy. 
Therefore while both p53-wt and p53-deficient cells became non-proliferative in response to 
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TMZ, the means by which this was accomplished differed in a manner consistent with p53 
status.  
 
 
Fig. 2. TMZ-induced cell cycle arrest and the fate of the cells. 
3. DNA checkpoint 
While both p53-wt and p53-deficient cells initiate G2/M arrest and become non-proliferative 
in response to TMZ, p53-wt cells which undergo prolonged G2/M arrest are less sensitive 
than p53-deficient cells to the cytotoxic actions of TMZ.  One possible explanation for this 
effect is that the prolonged G2/M arrest noted in p53-wt cells allows more time for reversal 
of the cytotoxic effects of the drug prior to entry into mitosis and death by mitotic 
catastrophe. G2/M arrest in response to TMZ may therefore represent a defense mechanism 
against the cytotoxic actions of TMZ. 
While the linkage between TMZ-induced DNA damage and G2/M arrest has not been fully 
explored, the linkage between irradiation-induced DNA damage and G2/M arrest has been 
shown to involve a pathway controlling the cyclin-dependent kinase cdc2. Various types of 
DNA damage activate Chk1 kinase which phophorylates cdc25C phosphatase at serine-216 
which enhances the binding of 14-3-3 proteins and the export of the cdc25C/14-3-3 complex 
to the cytoplasm. The cytoplasmic sequestration of phosphorylated cdc25C in turn 
eliminates the potential cdc25C-mediated dephosphorylation of cdc2. Cdc2 therefore 
remains bound to cyclin B in an inactive, phosphorylated state. The end result of DNA 
damage-induced Chk1 activation therefore is the phosphorylation of cdc2, and the arrest of 
cells with damaged DNA at the G2/M boundary. The ability of TMZ to induce DNA 
damage suggested that, like other DNA damaging agents, TMZ might initiate G2/M arrest 
via a Chk1-dependent pathway.  
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If Chk1 activation is critical in activation of G2/M arrest in TMZ-treated cells, and if G2/M 
arrest provides the opportunity for cells to avoid TMZ-induced cytotoxicity, inhibition of 
cdc2-dependent G2 arrest should sensitize cells to TMZ. A variety of small molecule 
inhibitors have recently been developed, and we analyzed the effect of UCN-01, a 
staurosporin derivative Chk1 inhibitor, as a pharmacologic tool to assess the linkage 
between TMZ exposure and G2/M arrest, to determine if G2/M arrest protects cells from 
TMZ-induced cytotoxicity, and to determine if Chk1 inhibitors might represent a way to 
sensitize cells to TMZ (Hirose et al., 2001b).     
To better define how TMZ induces G2/M arrest, we analyzed alterations in levels of G2-
checkpoint-associated proteins in TMZ-treated cells. The protein levels of Chk1 increased in 
a transient manner, rising at 1-2 days after TMZ exposure and returning to sub-control 
levels by 10 days after TMZ exposure. While total levels of cdc2 were unchanged or only 
slightly increased after TMZ, levels of phosphorylated cdc2 were transiently increased in 
both U87MG and U87MG-E6 cells in a timeframe and manner similar to that noted for 
induction of Chk1.  
To more directly test the association between TMZ and alterations in G2 checkpoint 
proteins, U87MG and U87MG-E6 cells were treated with TMZ, and then exposed to UCN-01 
for 3 days immediately following TMZ removal. Immunoblot analyses revealed that UCN-
01 reduced the level of phosphorylated cdc2 in the cells and significantly inhibited TMZ-
induced G2/M arrest of both U87MG and U87MG-E6 cells Furthermore, in agreement with 
the study described above, UCN-01 reduced TMZ-induced senescence-associated beta-
galactosidase activity and enhances mitotic catastrophe. UCN-01 increases TMZ-induced 
cytotoxicity in both p53-wt and p53-deficient glioma cells (Figure 3).  
 
 
Fig. 3. p53-independent sensitization of glioma cells to TMZ by Chk1 inhibitor UCN-01. 
Having established an association between TMZ-exposure, Chk1 activation, and TMZ-
induced G2/M arrest, we examined the hypothesis that G2/M arrest is a protective 
response of cells to TMZ-induced cytotoxicity, and that elimination of the G2 checkpoint 
might sensitize cells (and in particular p53-wt cells) to TMZ. In p53 wt cells, which undergo 
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a p53-associated prolonged G2/M arrest and senescence in response to TMZ, UCN-01 post-
treatment greatly reduced the extent of G2/M arrest, reduced the percentage of cells 
undergoing TMZ-induced senescence, and increased the percentage of cells undergoing 
mitotic catastrophe. These results clearly suggested that in p53-proficient glioma cells, the 
G2 checkpoint serves a protective function, and that elimination of the checkpoint is 
associated with an increase in the number of cells that die by pre-mature entry into mitosis. 
UCN-01, however, not only sensitized p53-wt cells but also p53-deficient cells which 
underwent only a transient G2/M arrest in response to TMZ. This sensitization did not 
involve changes in TMZ-induced senescence (which was minimal in these cells) but rather 
was associated exclusively with increases in the number of cells undergoing mitotic 
catastrophe (Figure 4).  
 
 
Fig. 4. Enhancement of TMZ-induced mitotic catastrophe by UCN-01. 
While increased levels of MGMT and loss of MMR capacity can both confer TMZ resistance, 
very few gliomas over-express MGMT or are MMR deficient. It appears likely, therefore that 
at least some of the resistance of gliomas to TMZ involves events downstream of futile MMR 
activation. The ability of UCN-01 to prevent downstream events which may contribute to 
TMZ resistance may therefore prove useful in the treatment of TMZ-resistant as well as 
TMZ-sensitive tumors. As approximately two-thirds of gliomas have defects in the p53 
pathway, the ability of UCN-01 to sensitize cells regardless of p53 status also increases the 
range of tumors for which this approach might be effective.  While issues relating to 
duration of exposure, drug sequencing, and the events that link MMR to Chk1 activation 
remain to be examined, it has been suggested that the combinations of TMZ with G2 
checkpoint inhibitors such as UCN-01 might be useful additions to existing therapies for 
brain tumors. 
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4. Stress-activated kinases 
Stress-activated kinases (SAPKs) could be targeted in an effort to enhance the effect of 
chemotherapeutic agents because the tumor cells, which grow under various types of 
cellular stress including hypoxia and genetic instability, might survive in severe 
environment by modifying on stress-inducing events. We here discuss about two SAPKs, 
p38MAPK and c-Jun-N-terminal kinase (JNK). 
4.1 p38 MAPK 
While the cellular response to methylating agent exposure appeared highly dependent on 
DNA repair processes influenced by the G2 cell cycle checkpoint, the purpose of the cell 
cycle arrest remains unclear, although it has long been suggested that cell cycle arrest 
provides cells that have incurred DNA damage time in which to reverse the damage.  
Despite this suggestion has not been directly tested, it was clear that the prolonged G2 arrest 
noted in glioma cells exposed to cytotoxic methylating agents alters their response.   
It has been appreciated for some time that cells lacking a functional MMR system undergo 
neither G2 arrest nor cytotoxicity in response to methylating agents, clearly suggesting a 
link between MMR and G2 arrest.  
A potential signaling pathway that might help connect activation of the MMR system to G2 
arrest is that controlled by the p38 MAPK family.  The p38 family of stress kinases contains 
four members: , , , and .  These MAP kinases are activated by the upstream kinases 
MKK3 and/or MKK6 in response to diverse stimuli including environmental stress and 
growth factors.  p38 kinases in turn activate a variety of downstream targets including 
MAPKAP2, the C/EBP family of transcription factors, and various other transcription 
factors including p53.  In this manner p38 is believed to play an important, although not 
well defined, role in co-ordinating a variety of cellular events including cell growth, cell 
differentiation, and cell death. At least two recent studies have suggested that the ability of 
the p38 pathway to co-ordinate cell growth and cell death might also extend to actions on 
cell cycle progression. 
To begin to address the possible role of the p38 pathway in the response of cells to 
methylating agents, we exposed U87MG cells to TMZ, and the various p38 isoforms were 
then immunoprecipitated from the nuclear fractions, and equal amounts of the 
immunoprecipitated p38 isoforms from each time point were incubated with the p38 
substrate ATF2 in the presence of ATP. TMZ exposure stimulated p38 kinase activity and 
p38 kinase activity was also modestly stimulated while the activity of p38 and  were not 
significantly affected (Hirose et al, 2003).  
To investigate linkage between MMR and p38 activation, we first exposed MMR-deficient 
HCT116 human colorectal adenocarcinoma cells and paired MMR-proficient HCT116 cells 
containing a copy of Mlh1-containing chromosome 3 (HCT116 3-6 cells) to TMZ, after which 
the cells were collected and analyzed for levels of p38 phosphorylation/activation and 
extent of G2 arrest by Western blot and by FACS analysis, respectively.  Neither HCT116 
nor HCT116 3-6 cells exhibited p38 induction or G2 arrest in the first two days following 
TMZ exposure, consistent with previous studies showing that both these cell lines are 
MGMT-proficient and presumably repair TMZ-induced O6-methylguanine before these 
lesions mispair with thymine and trigger downstream consequences. Following exposure to 
the highly specific MGMT depleting agent O6-benzylguanine prior to and after TMZ 
exposure, however, the MMR-proficient HCT116 3-6 cells exhibited TMZ-induced p38 
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activation in a manner similar to that noted in U87MG glioma cells, and underwent G2 
arrest.  O6-benzylguanine-exposed, TMZ-treated MMR-deficient HCT116 cells, however, 
exhibited neither p38 activation nor G2 arrest. These results suggested in a preliminary 
manner that p38 activation in response to TMZ is dependent on O6-methylguanine lesions 
and on the recognition and/or processing of these lesions by the DNA MMR system. 
While studies in HCT cells suggested an association between the DNA MMR system and 
TMZ-induced G2 arrest, the MMR-corrected HCT116 3-6 cell line used was derived from a 
clone that contains a large portion of human chromosome three, and which therefore could 
differ from the MMR-proficient HCT116 cells in ways more dependent on clonal selection 
and multiple gene expression that on direct correction of the MMR defect.  We therefore also 
examined TMZ-induced p38 activation and G2 arrest in MGMT-deficient, MMR-proficient 
human U87MG glioblastoma cells and in paired cells made MMR-deficient by expression of 
a retrovirally-encoded siRNA targeted to the MMR protein MLH1.  Expression of the 
retrovirally encoded MLH1 siRNA blocked TMZ-induced G2 arrest such that cells 
expressing the MLH1 siRNA, but not cells expressing the blank vector, avoided TMZ-
induced G2 arrest in a manner identical to that noted in HCT116 cells in which MLH1 was 
eliminated by mutation.  More importantly, siRNA-mediated reduction of MLH1 levels also 
blocked the ability of the cells to activate the p38 pathway.  These results, in connection with 
those derived from the studies with HCT cells, suggested that p38 activation was a common 
response of human cells to the methylating agent TMZ, that this activation is dependent on 
a functional MMR system, and that p38 activation is associated with methylating agent-
induced G2 arrest. 
 
 
Fig. 5. TMZ-induced p38 activation in MMR-deficient colon carcinoma cells (A) and MMR-
silenced glioma cells (B). 
Having demonstrated the linkage between DNA MMR and p38 activation, we wished to 
more clearly define the potential linkage between p38 activation and G2 arrest.  To do so we 
used both pharmacologic and genetic inhibitors of p38, and monitored the effects of these 
inhibitors on G2 checkpoint proteins and on TMZ-induce G2 arrest.  For pharmacologic 
inhibition studies, MGMT-deficient, MMR-proficient U87MG cells were exposed to the 
p38/ selective inhibitors SB203580 or SB202190 prior to and following TMZ exposure, 
after which effects of p38 inhibition on TMZ-induced p38 activation, activation of the G2 
checkpoint pathway, and activation of the G2 checkpoint itself were examined. Both 
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compounds not only blocked TMZ-induced p38 activation but also dramatically inhibited 
the ability of U87 cells to undergo G2 arrest two days following TMZ exposure.  Exposure of 
cells to SB203580 prior to and following TMZ exposure blocked the inactivation of both 
cdc25C and cdc2, consistent with the inability of SB compound-treated cells to undergo G2 
arrest following TMZ exposure. SB203580 exposure, however, had no significant effect on 
TMZ-induced Chk1 or Chk2 activation.  These results suggest that the p38 pathway, and 
p38/ specifically, are linked not only to MMR but also to activation of the G2 checkpoint 
through Chk1/2-independent actions on cdc25C and/or cdc2. 
We also employed genetic means to selectively inhibit p38 and to assess the consequences 
of p38 inhibition on the G2 arrest pathway.  To do so, MGMT-deficient, MMR-proficient 
U87MG cells were transfected with a pool of siRNA targeting p38, after which the cells 
were exposed to TMZ.  Transfection of U87MG cells with p38 siRNA reduced basal levels 
of p38, and blocked the TMZ-induced ability of immunoprecipitated p38 to 
phosphorylate the p38 substrate MAPKAP2 in vitro. Selective genetic inhibition of p38 
blocked TMZ-induced G2 arrest in U87MG cells in manner identical to that mediated by 
pharmacologic inhibitors of p38/.  Furthermore, as was noted in studies using 
pharmacological inhibitors, p38 siRNA blocked the phosphorylation/inactivation of both 
cdc25C and cdc2 without affecting TMZ-induced Chk1 or Chk2 activation (Figure 6). These 
results clearly show that p38 is activated by the DNA MMR system, and that this 
activation is in turn linked by Chk1- and Chk2-independent means to inactivation of cdc2, 
cdc25C, and ultimately to G2 arrest. 
 
 
Fig. 6. p38 inhibition potentiated TMZ-induced cytotoxicity 
Although pharmacologic or genetic inhibition of p38 did not alter clonagenicity, extent 
of senescence-associated beta-galactosidase expression, or extent of mitotic catastrophe, 
(data not shown), it did enhance the sensitivity of U87MG cells to TMZ-induced 
cytotoxicity, reducing the colony forming ability of these cells.  p38 inhibition increased 
the percentage of TMZ-treated cells that died by mitotic catastrophe, consistent with the 
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idea that cells incapable of undergoing G2 arrest enter mitosis with damaged DNA and 
die by mitotic catastrophe. These results suggest that p38 not only links MMR to the G2 
checkpoint, but also influences the response of cells to cytotoxic methylating agents. It 
would be reasonable to suspect that tumors capable of activating the G2 checkpoint via 
the p38 pathway would be less sensitive than those incapable of doing so. Conversely, 
because inhibition of p38 sensitizes cells to TMZ, p38 might be a reasonable therapeutic 
target.  
4.2 c-Jun N-terminal kinase 
Since p38, a major component of mitogen-activated protein kinases (MAPKs), had been 
shown to be involved in TMZ-induced cellular responses, we were interested other MAPKS 
in terms they could be target for chemosensitization. MAPKs are components of a complex 
intracellular signaling network that regulates gene expression in response to extracellular 
stimuli, in turn regulating cell proliferation, differentiation, and cell death. The MAPK 
family includes components of three major pathways in humans: p38 kinase, c-Jun NH2-
terminal kinase (JNK), and extracellular signal-regulated kinase. In the JNK pathway, 
specific stimuli activate various kinases leading to activation of JNK. Once activated, JNK is 
translocated to the nucleus, where it phosphorylates and activates transcriptional factors 
such as components of activator protein, including c-Jun, JunB, and JunD, as well as other 
factors including ATF-2 and STAT-3. As examples of the importance of JNK on cell 
signaling, JNK is associated with cell survival, oncogenesis, growth, differentiation, and cell 
death. The role of the JNK pathway in the mediation of cellular responses (including cellular 
transformation, cell growth, and cell death) to extracellular stimuli has been studied 
extensively. Interestingly, JNK can exert completely opposite effects depending on the cell 
type and stimuli. Since the question of whether JNK is associated with cell death or cell 
survival appeared to depend on the type of cellular stress, we investigated in the role of JNK 
in glioma cells treated with TMZ (Ohba et al., 2009). 
We first investigated whether JNK was activated in response to TMZ and confirmed the 
activation of JNK in glioma cells treated with TMZ. Previous studies on gliomas had 
already shown that JNK was activated and played a pro-survival role in response to the 
DNA crosslinking agent CDDP, and that the inhibition of the JNK pathway sensitized 
glioma cells to CDDP. Sensitization to chemotherapeutic agents by the inhibition of the 
JNK pathway has also been reported either in other cancer cells although, on the other 
hand, the inhibition of JNK reportedly led to the suppression of chemotherapeutic agent-
induced apoptosis in several studies. Therefore, we investigated the role of JNK in glioma 
cells treated with TMZ by utilizing the JNK inhibitor SP600125. As a result, we confirmed 
that SP600125 potentiated the TMZ-induced cytotoxicity in U87MG cells, and concluded 
that JNK activation played a cytoprotective role in glioma cells in response to TMZ-
induced DNA damage (Figure 7A). 
To clarify the mechanism responsible for the JNK inhibitor-induced potentiation of TMZ-
induced cytotoxicity, the two main downstream proteins of JNK, c-Jun and ATF-2, were 
investigated, since these proteins are believed to be associated with chemoresistance. In our 
study, because SP600125 inhibited the phosphorylation of c-Jun but not of ATF-2 at the low 
concentration at which SP600125 induced chemosensitization to TMZ, c-Jun-related 
responses were considered to be more important in the JNK-mediated survival of glioma 
cells treated with TMZ than ATF-2-related pathways (Figure 7B). 
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(A) 
 
 
(B) 
Fig. 7. Effect of JNK inhibitor SB600125 on TMZ-induced cytotoxicity (A) and 
phosphorylation of associated proteins (B). 
As noted above, the inhibition of p38 increased the sensitivity of glioma cells to TMZ in 
association with the abrogation of G2 arrest, however, in contrast, JNK inhibitor did not 
affect the cell cycle distribution of TMZ-treated cells nor changed the protein level of 
phosphorylated cdc2. Thus, the SP600125-induced chemosensitization to TMZ in glioma 
cells was probably not a consequence of the abrogation of cell cycle arrest. Rather, JNK 
inhibition increased the percentage of senescence-like cells in U87MG cells and of mitotic 
catastrophe cells in U87MG-E6 cells after treatment with TMZ. These results suggest that the 
enhancement of TMZ toxicity by a JNK inhibitor in glioma cells was induced by the 
potentiation of cell death pathways induced by TMZ alone. These data might be in 
agreement with previous studies on gliomas which suggested involvement of the JNK 
pathway in DNA repair.. c-Jun-related responses could be key events in the JNK-mediated 
cytoprotection of glioma cells treated with TMZ, and further investigations of the 
involvement of c-Jun in the survival machinery of cells with DNA damage might promote 
the development of useful chemotherapeutic strategies against malignant gliomas. 
5. Survival-promoting protein Akt 
Survival promoting protein such as Akt, which is frequently activated in malignant gliomas,  
could be a target to enhance the effect of chemotherapeutic agents. 
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Whereas an extensive network of proteins are required to work together to initiate G2 arrest 
in response to DNA damage, a number of additional proteins have been reported to alter 
activation and maintenance of the G2 checkpoint. One of the most interesting of these is Akt, 
a member of the phosphatidylinositol-3 kinase family that is recruited to the cell membrane 
and activated in response to the generation of phospholipids by a variety of signaling 
pathways. Activated Akt in turn signals to a variety of key downstream molecules including 
mammalian target of rapamycin (mTOR), glycogen synthetase kinase 3, and S6 kinase, the 
sum of which is to suppress cell death and to promote cell survival. In addition to effects on 
apoptosis and cell metabolism, Akt activation has been reported to suppress activation of 
the G2 checkpoint in human colon carcinoma cells exposed to radiation. Whereas the 
mechanism by which Akt suppresses G2 arrest has not been defined, the observation that 
Akt influences the G2 checkpoint is of particular importance to the therapeutic application 
of TMZ whose cytotoxicity is influenced by the G2 checkpoint and which are frequently 
used in the treatment of PTEN-deficient, Akt overexpressing gliomas. Furthermore, because 
exposure of glioma cells to TMZ induces a senescence-like phenomenon and mitotic 
catastrophe, and because bypass of TMZ–induced G2 arrest by Chk1 inhibitors enhances, 
rather than suppresses, glioma cell death as described above, the consequences of potential 
Akt-mediated bypass of methylating agent–induced G2 arrest on cellular outcome remained 
uncertain. 
To investigate the effect of Akt activation in biological responses of glioma cells to DNA-
methylating compound, we created U87MD-derived cells of which Akt activity could be 
exogeneously controlled. U87MG human glioma cells were infected with a retroviral 
construct encoding a modified Akt (AktERM+) protein which, by virtue of deletion of the 
parathyroid hormone domain, fusion to a c-Src myristoylation signal, and fusion to a 
modified form of the mouse ER hormone binding domain, has been shown rapidly activated 
in response to 4-hydroxytamoxifen. The levels of AktER rose in response to exposures of 4-
hydroxytamoxifen (Figure 8A). 
Having created cells with inducible levels of activated Akt, we addressed the consequences of 
Akt pathway activation on TMZ-induced G2 arrest. In the absence of 4-hydroxytamoxifen, 
TMZ-treated U87MG-AktERM+ cells showed Cdc2 (Tyr15) phosphorylation/ inactivation, 
and G2 arrest 3 to 5 days following TMZ exposure. However, U87MG cells expressing the 
AktERM+ construct exhibited significant inhibition of TMZ-induced phosphorylation/ 
inactivation of Cdc2, and TMZ-induced G2 arrest (Figure 8B).  
As described above, inhibition of TMZ-induced G2 arrest by Chk1 inhibitor forced cells into 
mitosis and enhances cell death by mitotic catastrophe in both p53-proficient and p53-
deficient glioma cells. We therefore questioned whether bypass of TMZ-induced G2 arrest 
by Akt, a protein known to suppress apoptosis in response to radiation-induced DNA 
damage, would sensitize cells to TMZ or instead protect cells by suppressing pathways 
linked to senescence and/or mitotic catastrophe. As a result, AktERM+ activation protected 
rather than sensitized the p53-proficient U87MG cells to TMZ-induced cytotoxicity (Figure 
8C). The cytoprotective effects of Akt overexpression were associated with a reduction in the 
percentage of cells expressing senescence-associated beta-galactosidase activity following 
TMZ exposure, suggesting that Akt overexpression not only reduced the percentage of cells 
undergoing TMZ-induced G2 arrest but also reduced the ability of p53-positive glioma cells 
to undergo a senescence-like phenomenon in response to TMZ. Furthermore, AktERM+ 
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Fig. 8. Akt over-activation in U87MG-AktERM+ cells (A) and its effect on TMZ-induced cell 
cycle arrest (B) and cytotoxicity (C) 
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overexpression in U87MG-E6 cells suppressed not only TMZ-induced G2 arrest and loss of 
clonogenicity but also the percentage of cells undergoing death by mitotic catastrophe 
following TMZ exposure. These results suggest that Akt overexpression, whereas 
suppressing TMZ-induced G2 arrest, also protects cells from loss of clonogenicity caused by 
induction of senescence and mitotic catastrophe. 
In summary, the results showed that Akt activation suppresses the G2 checkpoint by 
selectively altering activation of the DNA damage signal transducer Chk2 and the 
downstream effectors of the G2 checkpoint. The overriding effect of Akt activation, 
however, is suppression of TMZ-induced senescence and mitotic catastrophe in cells that 
avoid G2 arrest. The Akt pathway may therefore contribute to TMZ resistance in the clinical 
setting. 
It is interesting to note that most high-grade human gliomas have high levels of Akt 
activation, which are believed to be a consequence of PTEN deletion. Given the role Akt 
plays in moving cells through the G2 checkpoint and in suppressing TMZ-induced 
cytotoxicity, it seems likely that an analysis of Akt pathway activation in gliomas before 
therapy may help identify those individuals for whom TMZ-based therapies are most likely 
to succeed. Similarly, strategies combining TMZ with inhibitors of the Akt pathway may 
enhance the likelihood of success. Because Akt overexpression has also been reported to 
increase the mutagenicity of agents that induce G2 arrest, presumably by promoting cell 
survival in the absence of genuine DNA repair, strategies designed to suppress Akt may 
contribute not only to improved tumor cell kill but also to suppression of unwanted 
mutagenic effects which might otherwise contribute to secondary malignancies.  
6. Molecular chaperone 90kD heat shock protein 
As reviewed above, several ways to potentiate the cytotoxicity of TMZ have been reported, 
and thus many pathways can be targeted in an effort to sensitize tumor cells to 
chemotherapeutic agents. A molecular chaperone, 90kD heat shock protein (hsp90) has 
recently attracted attention as a sensitizing agent because it is expressed at 2–10-fold higher 
levels in tumor tissue than in normal tissue, and is associated with many proteins (termed 
client proteins) involved in cell cycle regulation, cell survival and oncogenesis. Taken 
together, these studies indicated that many hsp90 client proteins are involved in 
cytoprotective mechanisms against cellular stressors such as DNA damage, suggesting that 
hsp90 might be important in the survival of tumor cells after exposure to DNA-damaging 
chemotherapeutic agents. Therefore we hypothesized that hsp90 inhibitors might act as 
antitumor agents against gliomas and might potentiate the cytotoxicity of DNA-damaging 
agents.  
To investigate this hypothesis, we used 17-AAG, a geldanamycin derivative, as a 
pharmacological inhibitor of hsp90 and examined whether an hsp90-targeted strategy could 
be useful for chemosensitizing glioma cells to the DNA-damaging agents BCNU, cisplatin, 
and TMZ (Ohba et al., 2010). 
The clonogenicity of cells treated with cisplatin, BCNU, or TMZ was depressed with 17-
AAG. This 17-AAG–induced potentiation of the effects of these chemotherapeutic agents 
was recognized at a lower concentration than that needed to induce cytotoxicity with 17- 
AAG alone, and was more remarkable in the cisplatin- and BCNU-treated cells than in the 
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TMZ-treated cells. Isobologram analyses revealed that the interactions between 17-AAG and 
cisplatin or BCNU were synergistic, whereas the interaction between 17-AAG and TMZ was 
no more than additive (Figure 9).  
The FACS analyses revealed that the population of cells with a sub-G1 DNA content was 
increased by combined treatment with 17-AAG and either cisplatin or BCNU; furthermore, 
the combined treatment remarkably increased the number of annexin V–positive and PI-
negative cells. These results demonstrated that the 17-AAG– induced enhancement of the 
DNA crosslinking agents–induced cytotoxicity was either associated in part or entirely with 
an increase in apoptotic cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Effect of Hsp90 inhibitor 17-AAG on cytotoxicity induced by various DNA damaging 
agents.  
A reasonable concern is that hsp90 inhibitors may act not only on tumor cells, but also on 
normal cells; however, the authors of previous studies have shown that hsp90 is expressed 
at 2–10-fold higher levels in tumor than in normal tissue, and that hsp90 derived from 
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tumor cells has a 100-fold higher binding affinity for the hsp90 inhibitor 17-AAG than does 
hsp90 derived from normal cells. These data suggest that the effect of hsp90 inhibitors on 
normal cells may be much smaller than that on tumor cells and that an hsp90 inhibitor 
might therefore be useful for selectively killing tumor cells.  
The mechanism of the 17-AAG–induced enhancement of the cytotoxicity of DNA-
crosslinking agents has not yet been completely elucidated, and suppression of other 
survival-promoting factor(s) could be involved in enhancement of DNA-damaging agents, 
however. 
7. Conclusion 
We reviewed our studies focusing chemosensitization of gliomas. We propose that 
combination of conventional chemotherapy using DNA-damaging agents and molecular 
targeted therapy could be a potentially useful new antiglioma therapeutic strategy. 
However, enhancement of the effect of chemotherapeutic agents clearly depends on the 
mechanism by these compounds exhibit cytotoxicity. Therefore the development of a safe 
and effective therapeutic regimen will require further investigation 
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